Integer Holdings Corp, a major player in contract development and manufacturing for specialized medical devices, reported steady operating income growth in 2025 despite net income contraction. The firm exited the portable medical device market to concentrate on higher-growth areas such as cardiac rhythm management and neuromodulation, bolstered by recent acquisitions that enhance proprietary coating technologies. Operational risks include customer concentration, leverage from convertible debt, and regulatory pressures. Capital allocation shows modest share repurchases with no disclosed dividends and a strong liquidity profile. Going forward, revenue growth will hinge on successful integration of acquisitions and expansion in targeted segments amid competitive headwinds.